Frank Armstrong

Dr Armstrong (b. 1957) has held Chief Executive roles with five biotechnology companies, both public and private, including Fulcrum Pharma plc and CuraGen. He led Medical Science and Innovation at Merck Serono and was previously Executive Vice President of Product Development at Bayer and Senior Vice President of Medical Research and Communications at Zeneca.

Dr Armstrong is currently the Chairman of Caldan Therapeutics, Enhanc3D Genomics and BioCaptiva, a Director of Newcells Biotech and a Non-Executive Director of ECO Animal Health Group plc, as well as a member of the Senior Advisory Board at Healthcare Royalty Partners and

Epidarex Capital.

Dr Armstrong received an honours degree in biochemistry and an MBChB, Bachelor of Medicine, Bachelor of Surgery from the University of Edinburgh, Scotland. He is a physician, a Fellow of the Royal College of Physicians of Edinburgh and Non-Executive Director of the University of Edinburgh’s governing body, the University Court.

He was appointed to the Board as a Non-Executive Director in September 2015.